What is claimed is:

1. A cell comprising a modification in a gene selected from the group consisting of FAS, BID, CTLA4, PDCD1, CBLB, PTPN6, B2M, TRAC and TRBC genes, wherein the cell is modified by delivering a complex comprising a CRISPR from *Prevotella* and *Franciscella* 1 (Cpf1) RNA-guided nuclease and a gRNA that targets a gene selected from the group consisting of FAS, BID, CTLA4, PDCD1, CBLB, PTPN6, B2M, TRAC and TRBC genes.

2. The cell of claim 1, wherein the complex targets a site in the gene selected from the group consisting of FAS, BID, CTLA4, PDCD1, CBLB, PTPN6, B2M, TRAC and TRBC genes, which site comprises a target domain and an $(T)_xN$ sequence, wherein the x is 1-10 and N is A, G, C, or T.

3. The cell of claim 1 or 2, wherein the modification comprises a deletion/insertion of, or a mutation in all or part of the gene selected from the group consisting of FAS, BID, CTLA4, PDCD1, CBLB, PTPN6, B2M, TRAC and TRBC genes.

4. The cell of any one of claims 1-3, wherein the cell comprises a modification in at least two of the genes selected from the group consisting of FAS, BID, CTLA4, PDCD1, CBLB, PTPN6, B2M, TRAC and TRBC genes.

5. The cell of any one of claims 1-4, wherein expression of the gene selected from the group consisting of FAS, BID, CTLA4, PDCD1, CBLB, PTPN6, B2M, TRAC and TRBC genes in the modified cell is modulated.

6. The cell of any one of claims 1-5, wherein the cell is:

(a) a T cell selected from the group consisting of: a $CD8^+$ T cell, a central memory T cell, an effector memory T cell, a $CD4^+$ T cell, a natural killer T cell (NK T cell), a regulatory T cell (Treg), and a stem cell memory T cell;

(b) a lymphoid progenitor cell;

(c) a hematopoietic stem cell;

(d) a natural killer cell (NK cell);

(e) a dendritic cell; or

(f) an induced pluripotent stem (iPS) cell or a cell derived from an iPS cell.

○

7. The cell of claim 6, wherein the T cell is a $CD8^+$ T cell.

8. The cell of claim 7, wherein the $CD8^+$ T cell is a $CD8^+$ naïve T cell, a central memory T cell, or an effector memory T cell.

9. The cell of any one of claims 1-8, wherein the cell is an engineered cell.

10. The modified cell of claim 9, wherein the engineered cell is an engineered chimeric antigen receptor (CAR) T cell or an engineered TCR (T cell receptor) T cell.

11. The cell of any one of claims 1-10, wherein the modification is within the first exon of the gene selected from the group consisting of FAS, BID, CTL4A, PDCD1, CBLB, PTPN6, B2M, TRAC and TRBC genes.

12. The cell of any one of claims 1-10, wherein the modification is within 500 bp of the coding sequence downstream from the start codon of the gene selected from the group consisting of FAS, BID, CTL4A, PDCD1, CBLB, PTPN6, B2M, TRAC and TRBC genes.

13. An *ex vivo* method of modifying a cell, comprising contacting the cell with a composition comprising:

(a) a gRNA molecule comprising a targeting domain that is complementary to a sequence of a gene selected from the group consisting of FAS, BID, CTLA4, PDCD1, CBLB, PTPN6, B2M, TRAC and TRBC genes; and

(b) a Cpf1 RNA-guided nuclease.

14. The method of claim 13, wherein said contacting comprises introducing the composition into the cell by electroporation.

15. The method of claim 13, wherein the composition comprises an ribonucleoprotein (RNP) complex comprising the gRNA molecule and the Cpf1 RNA-guided nuclease.

16. The method of claim 13, the composition comprises the gRNA molecule and a nucleic acid capable of expressing the Cpf1 RNA-guided nuclease in the cell.

○

17. A population of cells, wherein the cells comprise a modification in a gene selected from the group consisting of FAS, BID, CTLA4, PDCD1, CBLB, PTPN6, B2M, TRAC and TRBC genes, wherein the modification is made by delivering a complex comprising a Cpf1 RNA-guided nuclease and a gRNA molecule that targets the gene selected from the group consisting of FAS, BID, CTLA4, PDCD1, CBLB, PTPN6, B2M, TRAC and TRBC genes.

18. The population of claim 17, wherein the cells are selected from the group consisting of:
(a) T cells selected from the group consisting of $CD8^+$ T cells, central memory T cells, effector memory T cells, $CD4^+$ T cells, NKT cells, regulatory T cells (Tregs), and stem cell memory T cells;
(b) lymphoid progenitor cells;
(c) hematopoietic stem cells;
(d) NK cells;
(e) dendritic cells; or
(f) iPS cells or cells derived from iPS cells.

19. The population of claim 18, wherein the T cell is a $CD8^+$ T cell.

20. The population of claim 19, wherein the $CD8^+$ T cell is a $CD8^+$ naïve T cell, a central memory T cell, or an effector memory T cell.

21. The population of any one of claims 17-20, wherein the modified cells are engineered cells.

22. The population of claim 21, wherein the engineered cells are engineered chimeric antigen receptor (CAR) T cells or engineered TCR (T cell receptor) T cells.

23. A gRNA comprising a targeting domain selected from the group set forth in SEQ ID NOs: 1-3707 of Table 1.

24. A method of treating a subject having cancer, comprising:
(a) modifying a cell of the subject *ex vivo* or *in vitro* with:
(i) a Cpf1 RNA-guided nuclease; and

○

(ii) a gRNA molecule comprising a targeting domain complementary to a target domain from a gene selected from the group consisting of FAS, BID, CTLA4, PDCD1, CBLB, PTPN6, B2M, TRAC and TRBC genes; and

(b) returning the modified cell to the subject.

25. The method of claim 24, wherein the cancer is selected from the group consisting of: lymphoma, chronic lymphocytic leukemia (CLL), B cell acute lymphocytic leukemia (B-ALL), acute lymphoblastic leukemia, acute myeloid leukemia, non-Hodgkin's lymphoma (NHL), diffuse large cell lymphoma (DLCL), multiple myeloma, renal cell carcinoma (RCC), neuroblastoma, colorectal cancer, breast cancer, ovarian cancer, melanoma, sarcoma, prostate cancer, lung cancer, esophageal cancer, hepatocellular carcinoma, pancreatic cancer, astrocytoma, mesothelioma, head and neck cancer, and medulloblastoma.

26. A modified immune cell comprising a modification in one or more genes selected from the group consisting of TRAC, TRBC and B2M genes, wherein the one or more genes are modified using an RNP complex comprising a Cpf1 RNA-guided endonuclease and one or more gRNAs, wherein the gRNA comprises a targeting domain that is complementary to a nucleic acid sequence of one or more the genes selected from the group consisting of TRAC, TRBC and B2M genes.

27. The modified immune cell of claim 26, wherein the RNP complex is delivered into the immune cell via electroporation.

○